Table 3.
Baseline Characteristics of the COPD and healthy subjects that donated blood for the MDM eosinophil efferocytosis assays
| COPD (n = 17) | Control (n = 8) | P value | |
|---|---|---|---|
|
Male, n (%) |
10 (58.8) |
4 (50) |
1 |
|
Age (years)* |
68.05 (2.3) |
54.1 (4.7) |
0.006 |
|
Body mass index (kg/m
2
) |
27.17 (1.36) |
33 (29–34) |
0.07 |
|
Never-smokers n (%) |
0 (0) |
6 (75) |
0.0002 |
|
Pack years smoked |
42 (31–70) |
13 (5–22) |
0.05 |
|
COPD duration (years) |
9.6 (8–13) |
NA |
NA |
|
Exacerbations in last year |
1 (1–2) |
NA |
NA |
|
ICS dose (BDP equivalent) (mcg/day) |
2000 (1600–2000) |
NA |
NA |
|
FEV
1
% predicted, (%) |
43 (5.1) |
95 (85–110) |
<0.0001 |
|
FEV
1
post bronchodilator (L) |
1.13 (0.14) |
2.8 (2.5-3.8) |
0.0004 |
|
Post FEV
1
/FVC (%) |
48.6 (4.23) |
84.08 (1.7) |
<0.0001 |
|
Reversibility, % |
5.67 (2.17) |
0.57 (-1.9-9) |
0.45 |
|
Sputum Total cell count ×10
6
/g |
3.3 (1.5-6.7) |
NA |
NA |
|
Sputum neutrophils (%) |
65 (40–80) |
NA |
NA |
|
Sputum eosinophils (%) |
7.3 (4.5-15) |
NA |
NA |
|
GOLD 1, n (%) |
0 (0) |
NA |
NA |
|
GOLD 2, n (%) |
7 (41.2) |
NA |
NA |
|
GOLD 3, n (%) |
5 (29.4) |
NA |
NA |
|
GOLD 4, n (%) |
5 (29.4) |
NA |
NA |
|
Blood neutrophils (×10
9
/L) |
4.66 (3.67-5.94) |
3.5 (2.6-4.5) |
0.03 |
|
Blood eosinophils (×10
9
/L) |
0.21 (0.08-0.36) |
0.15 (0.11-0.34) |
0.86 |
|
CRP (mg/dl) |
5 (<5-8) |
5 (<5-5.75) |
0.95 |
|
Bacterial colonisation, n (%) |
3 (17.6) |
NA |
NA |
|
CFU unit/ml** |
6.5 (5.6-7) |
NA |
NA |
|
MRC dyspnoea scale |
3 (2–4) |
NA |
NA |
|
SGRQ total score |
54 (41–66) |
NA |
NA |
|
CRQ total score |
4.1 (3.2-5.7) |
NA |
NA |
|
VAS cough (mm) |
26 (11.5-67.5) |
NA |
NA |
|
VAS dyspnoea (mm) |
50 (36–64) |
NA |
NA |
|
VAS sputum production (mm) |
23.7 (6–63) |
NA |
NA |
| VAS sputum purulence (mm) | 12.4 (6–62) | NA | NA |
Data presented as median (IQR) unless stated, *mean (SEM), **Geometric mean of Log data (95% CI). SEM: standard error of mean, CI: confidence interval.
Abbreviations:AUC Area under the curve, BDP Beclometasone dipropionate, CFU Colony forming unit, CRQ Chronic Respiratory Questionnaire, CRP C-reactive protein, FEV1 Forced expiratory volume in 1 second, FVC Forced vital capacity, GOLD Global Initiative for Chronic Obstructive Lung Disease; ICS Inhaled corticosteroids, MRC Medical Research Council, SGRQ St George’s Respiratory Questionnaire, TCC Total cell count, VAS Visual analogue score.